Syros Pharmaceuticals, Inc. (SYRS)
| Market Cap | 814.86M |
| Revenue (ttm) | 9.90M |
| Net Income (ttm) | -73.64M |
| Shares Out | 45.78M |
| EPS (ttm) | -1.65 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 20 |
| Last Price | $13.16 |
| Previous Close | $14.95 |
| Change ($) | -1.79 |
| Change (%) | -11.97% |
| Day's Open | 15.00 |
| Day's Range | 12.85 - 15.25 |
| Day's Volume | 3,657,017 |
| 52-Week Range | 4.46 - 15.25 |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, announced today that it is offering to se...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today outlined its strategic priorities a...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Conference date in details should read: Thursday, January 14 (instead of Thursday, January 7) The updated release reads: SYROS TO PRESENT AT 39TH ANNUAL J.P....
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive ...
Syros Pharmaceuticals doubled its stock price in 2020. Syros recently acquired SY-2101 from Orsenix.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, announced today that it has closed a prev...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced new clinical data from it...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it has acquired from...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive ...
Syros Pharmaceuticals' (SYRS) CEO Nancy Simonian on Q3 2020 Results - Earnings Call Transcript
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present new ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced initial safety, pharmacok...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present init...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of S.
Syros (SYRS) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Syros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q2 2020 Results - Earnings Call Transcript
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 5.00% and 45.57%, respectively, for the quarter ended June 2020.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Financial ...
Syros Pharmaceuticals, Inc. (SYRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live ...
Top Ranked Momentum Stocks to Buy for May 19th
Syros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q1 2020 Results - Earnings Call Transcript
Syros Pharmaceuticals Inc (SYRS) delivered earnings and revenue surprises of 13.33% and 38.31%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for...
Shares of Syros Pharmaceuticals (NASDAQ:SYRS) were unchanged in pre-market trading after the company reported Q1 results.
Syros Pharmaceuticals, Inc. (SYRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Syros Pharmaceuticals (SYRS) CEO Nancy Simonian on Q4 2019 Results - Earnings Call Transcript
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 2.13% and -35.53%, respectively, for the quarter ended December 2019.
Syros Pharmaceuticals, Inc. (SYRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
As of late, it has definitely been a great time to be an investor Syros Pharmaceuticals
Investors appeared to like the addition of a well-known new board member.
Syros Pharmaceuticals (SYRS) news for Wednesday about plans for developing new drugs and a $20 million payment have SYRS stock flying high.
Global Blood Therapeutics Inc. and Syros Pharmaceuticals announced a partnership to develop and commercialize therapies for sickle cell disease and beta thalassemia.
Companies in the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining regulatory approval.
Syros Pharmaceuticals' (SYRS) CEO Nancy Simonian on Q3 2019 Results - Earnings Call Transcript
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 2.08% and 29.77%, respectively, for the quarter ended September 2019.
While most of Wall Street focuses on large and mega cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
Syros Pharmaceuticals, Inc. (SYRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Syros Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Not every stock had a favorable reaction to earnings.
Syros Pharmaceuticals (SYRS) CEO Nancy Simonian on Q2 2019 Results - Earnings Call Transcript
Syros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q1 2019 Results - Earnings Call Transcript
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 14.04% and 7.58%, respectively, for the quarter ended March 2019.
Syros plunged 33% on Friday, April 5, after announcing a stock offering.
The company announced the pricing of a stock offering. Despite the dilution, it's a well-timed move by management.
About SYRS
Syros Pharmaceuticals, a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subset of patients with acute myeloid leukemia and myelodysplastic syndrome; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tum... [Read more...]
| Industry Biotechnology | IPO Date Jun 30, 2016 |
| CEO Nancy Simonian | Employees 83 |
| Stock Exchange NASDAQ | Ticker Symbol SYRS |
Financial Performance
In 2019, SYRS's revenue was $1.98 million, a decrease of -3.32% compared to the previous year's $2.05 million. Losses were -$75.44 million, 21.1% more than in 2018.
Analyst Forecasts
According to 8 analysts, the average rating for SYRS stock is "Buy." The 12-month stock price forecast is 17.43, which is an increase of 32.45% from the latest price.